ARS Pharmaceuticals
SPRY
74 hedge funds and large institutions have $287M invested in ARS Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 20 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
2.29% more ownership
Funds ownership: 80.18% → 82.46% (+2.3%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
3% less funds holding
Funds holding: 76 → 74 (-2)
67% less capital invested
Capital invested by funds: $864M → $287M (-$577M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $136K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$23.3M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$19.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.6M |
| 4 |
Morgan Stanley
New York
|
+$15.4M |
| 5 |
BlackRock
New York
|
+$8.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$35.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$13.8M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.85M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.39M |
SPRY Hedge Fund Activity: Q3 2021 in Review
74 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2021, worth a combined $287M — down 67% from $864M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SPRY and 19 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 36 added.
The largest buyer was Millennium Management, adding an estimated $23.3M. The largest seller was EcoR1 Capital, cutting an estimated $35.3M.
- 74 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2021, down from 76 in Q2 2021.
- Funds reported $287M of ARS Pharmaceuticals stock for Q3 2021, down 67% quarter-over-quarter.
- 19 funds opened new ARS Pharmaceuticals positions in Q3 2021 and 20 closed out, a net change of -1 holder.
- The largest ARS Pharmaceuticals buyer in Q3 2021 was Millennium Management, an estimated $23.3M added.
- The largest ARS Pharmaceuticals seller in Q3 2021 was EcoR1 Capital, an estimated $35.3M sold.
Based on aggregated 13F filings for Q3 2021.